However, the lack of an additional second molecular mechanism driven by JAK2 exon 16 mutations, unlike JAK2 p. V617F, may explain why ALL-associated JAK2 mutations require CRLF2 overexpression to cooperatively drive malignant transformation and subsequent leukemogenesis. The gene discussed is CRLF2; the disease is acute lymphoblastic leukemia.